Disease Domain | Count |
---|---|
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Mechanism κ opioid receptor agonists [+1] |
Active Org. |
Originator Org. ![]() |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date30 Jun 2010 |
Mechanism κ opioid receptor antagonists [+1] |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date29 Dec 1981 |
Mechanism 5-HT1A receptor agonists [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Sep 2016 |
Sponsor / Collaborator ![]() [+2] |
Start Date01 Sep 2016 |
Sponsor / Collaborator Healthcare Technology LabStartup [+1] |
Start Date20 Jun 2016 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Buprenorphine ( κ opioid receptor x μ opioid receptor ) | Opioid-Related Disorders More | Approved |
ATI-9242 ( 5-HT1A receptor x 5-HT2A receptor x 5-HT7 receptor x D2 receptor ) | Schizophrenia More | Pending |
Buprenorphine Hydrochloride ( κ opioid receptor x μ opioid receptor ) | Back Pain More | Pending |
Buprenorphine Hydrochloride/Granisetron ( 5-HT3 receptor x κ opioid receptor x μ opioid receptor ) | Pain, Postoperative More | Pending |